Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9

Trends in Biotechnology
Sergiu ChiraIoana Berindan-Neagoe

Abstract

With an increasing prevalence in the human population, cancer has become one of the most investigated fields of medicine. Among the potential targets for cancer therapy is the tumor suppressor gene TP53, which is found in a mutated state in approximately 50% of human cancers and is often associated with poor prognosis. We propose a novel, highly tumor-specific delivery system for TP53, based on the CRISPR/Cas9 genome editing technology. This system will restore the normal p53 phenotype in tumor cells by replacing the mutant TP53 gene with a functional copy, leading to sustained expression of p53 protein and tumor regression.

Citations

Jun 8, 2018·Cancers·Ramona Schulz-Heddergott, Ute M Moll
Sep 25, 2018·Critical Reviews in Biochemistry and Molecular Biology·Diana GuleiIoana Berindan-Neagoe
Jan 12, 2019·Expert Review of Molecular Diagnostics·Diana GuleiGeorge Adrian Calin
Aug 9, 2019·Journal of Clinical Medicine·Valentina SasUNKNOWN Romanian-Japanese Working Group of the Romanian Society for Bone Marrow Transplantation
Jul 8, 2020·Genes·Regina MirgayazovaEmil Bulatov
Sep 26, 2020·Frontiers in Oncology·Vitaly ChasovEmil Bulatov
Jul 22, 2018·Cellular and Molecular Life Sciences : CMLS·Cecilia Bica-PopIoana Berindan-Neagoe
Oct 2, 2019·Molecular Biology Reports·Muhammet Burak BatırFethi Sırrı Çam
Sep 24, 2019·Journal of Biotechnology·Gabriela Pannunzio Carmignotto, Adriano Rodrigues Azzoni
Sep 29, 2019·Molecular Aspects of Medicine·Diana GuleiIoana Berindan-Neagoe
Dec 31, 2019·Biotechnology Advances·Cui-Cui MaYu-Quan Wei
Oct 30, 2020·Frontiers in Immunology·Mohammadreza Azangou-KhyavyJafar Kiani

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.

Related Papers

Medizinische Monatsschrift für Pharmazeuten
Wolfgang Deppert
Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
R Gandour-EdwardsP J Donald
Proceedings of the National Academy of Sciences of the United States of America
Aaron J Schetter, Curtis C Harris
© 2022 Meta ULC. All rights reserved